Lithium Pharmacogenetics: Where Do We Stand?

Abstract excerpt

Preclinical Research Bipolar disorder (BPD) is a chronic and disabling psychiatric disorder with a prevalence of 0.8-1.2% in the general population. Although lithium is considered the first-line treatment, a large percentage of patients do not respond sufficiently. Moreover, lithium can induce severe side effects and has poor tolerance and a narrow therapeutic index. The genetics of lithium response has been...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bipolar Disorder and Treatment
• Share to Genetic Syndromes and Imprinting
• Share to Genetics and Neurodevelopmental Disorders